Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Parkinson's Disease

  Free Subscription


15.11.2021

1 Exp Neurol
1 J Neurosci
1 Mov Disord
1 Neurologia (Engl Ed)
1 Neurosci Lett
1 Rev Neurol


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Exp Neurol

  1. MA J, Sun W, Chen S, Wang Z, et al
    The long noncoding RNA GAS5 potentiates neuronal injury in Parkinson's disease by binding to microRNA-150 to regulate Fosl1 expression.
    Exp Neurol. 2021;347:113904.
    PubMed         Abstract available


    J Neurosci

  2. MANN LG, Hay KR, Song AK, Errington SP, et al
    D2-Like Receptor Expression in the Hippocampus and Amygdala Informs Performance on the Stop-Signal Task in Parkinson's Disease.
    J Neurosci. 2021 Nov 3. pii: JNEUROSCI.0968-21.2021.
    PubMed         Abstract available


    Mov Disord

  3. SURFACE M, Balwani M, Waters C, Haimovich A, et al
    Plasma Glucosylsphingosine in GBA1 Mutation Carriers with and without Parkinson's Disease.
    Mov Disord. 2021 Nov 6. doi: 10.1002/mds.28846.
    PubMed         Abstract available


    Neurologia (Engl Ed)

  4. VALLDEORIOLA F, Grandas F, Arbelo JM, Blazquez Estrada M, et al
    Spanish expert consensus on the use of safinamide in Parkinson's disease.
    Neurologia (Engl Ed). 2021;36:666-672.
    PubMed         Abstract available


    Neurosci Lett

  5. PENGV B, Gong Z, Zhang Y, Shen B, et al
    Self-paced learning and privileged information Based KRR classification algorithm for diagnosis of Parkinson's disease.
    Neurosci Lett. 2021 Oct 29:136312. doi: 10.1016/j.neulet.2021.136312.
    PubMed         Abstract available


    Rev Neurol

  6. CAMPO-PRIETO P, Santos-Garcia D, Cancela-Carral JM, Rodriguez-Fuentes G, et al
    [Current status of immersive virtual reality as a tool for physical and functional rehabilitation in patients with Parkinson s disease: systematic review].
    Rev Neurol. 2021;73:358-367.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Parkinson's Disease is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: